Sensei Bio Begins Key Trial for Dual-Attack Cancer Drug in Advanced Breast Cancer

BOSTON – May 05, 2026 – Sensei Biotherapeutics has initiated a pivotal clinical trial for a novel, all-oral cancer therapy, PIKTOR, targeting a large and underserved population of patients with advanced breast cancer. The company announced today that the first patient has been dosed in a Phase 1b/2 study evaluating the drug in HR+/HER2- advanced breast cancer, a setting where many patients exhaust effective treatment options. The trial marks a critical step for PIKTOR, a combination therapy designed to outsmart cancer's resistance by attacking a key growth pathway at multiple points simultaneously. This program became the centerpiece of Sensei's pipeline following its strategic acquisition of Faeth Therapeutics earlier this year.

A New Strategy Against a Stubborn Foe

The trial addresses one of the most common and challenging forms of breast cancer. HR+/HER2- tumors account for the majority of breast cancer cases, and while initial treatments can be effective, many patients eventually see their disease progress and stop responding. A primary culprit behind this resistance is the PI3K/AKT/mTOR signaling pathway, a complex network that controls cell growth and survival. This pathway is abnormally activated in approximately half of all HR+/HER2- breast cancer cases.

For years, drug developers have targeted this pathway, but with limited success. Existing approved drugs, such as the PI3K inhibitor alpelisib (Piqray) or the mTOR inhibitor everolimus (Afinitor), each block only a single node in the network. This single-point attack often allows the highly adaptable cancer cells to find a detour, rerouting growth signals through other parts of the pathway that remain active. This biological workaround is a common reason for treatment failure and disease progression.

PIKTOR represents a fundamentally different approach. It is not a single drug but an all-oral combination of two distinct molecules: serabelisib, which blocks PI3K-alpha, and sapanisertib, which dually inhibits mTORC1 and mTORC2. By targeting these crucial nodes simultaneously, the therapy is designed to create a more comprehensive and durable blockade of the entire pathway, potentially preventing the cancer's escape routes and overcoming the resistance that plagues single-agent therapies.

Building on Promising Early Results

The decision to advance PIKTOR into this major breast cancer trial is not a leap of faith. It is built on a foundation of compelling early data from a prior investigator-initiated Phase 1b study. That trial evaluated PIKTOR, combined with the chemotherapy paclitaxel, in a group of patients with advanced breast, endometrial, and ovarian tumors who were largely out of standard options. These were heavily pre-treated individuals who had failed an average of four previous lines of therapy.

The results were striking. Nearly half of the 15 evaluable patients (47%) saw their tumors shrink, a significant overall response rate in such a difficult-to-treat population. The effect was even more pronounced in the subset of patients whose tumors were known to have mutations in the PI3K pathway. Within this group, an impressive 71% of patients responded to the treatment.

Perhaps most encouragingly, three patients experienced a complete response, meaning all signs of their cancer disappeared. All three of these complete responses occurred in patients with endometrial cancer, a disease where PI3K pathway alterations are particularly common. This robust early signal has provided Sensei with the confidence to pursue PIKTOR's development aggressively.

"In our earlier trial, patients who had exhausted multiple lines of therapy, including chemotherapy, responded to the PIKTOR plus paclitaxel combination, and several had complete responses,” said Anand Parikh, Chief Operating Officer of Sensei Biotherapeutics, in the company's announcement. “PIK-101 now takes that same oral combination into breast cancer, where a large share of tumors carry the pathway alterations that PIKTOR is designed to target."

Sensei's Strategic Pivot to PIKTOR

The advancement of PIKTOR is the first major clinical milestone since Sensei Biotherapeutics underwent a significant strategic transformation. In February 2026, the company acquired Faeth Therapeutics in an all-stock transaction that immediately repositioned PIKTOR as its lead pipeline asset. The move signaled a clear shift in focus toward multi-node inhibition of critical cancer pathways.

To fuel this new direction, the acquisition was accompanied by a concurrent $200 million private placement from institutional investors. This substantial financial backing is intended to see the PIKTOR program through key clinical milestones, including topline data from the newly initiated breast cancer trial and an ongoing Phase 2 study in endometrial cancer.

The market has responded positively to this strategic pivot, with Sensei's stock (Nasdaq: SNSE) delivering significant returns over the past year. However, as is common with clinical-stage biotech firms, the company is investing heavily in its research and development, and the path forward depends entirely on the success of its clinical trials. The initiation of the PIK-101 study is therefore not just a scientific event, but a critical test of the company's new corporate strategy.

Navigating a Crowded and Complex Field

Sensei and PIKTOR are entering a competitive but fragmented therapeutic landscape. Several drugs targeting the PI3K/AKT/mTOR pathway are already on the market, including the aforementioned alpelisib and everolimus, as well as the recently approved AKT inhibitor capivasertib (Truqap). While these drugs validate the pathway as a therapeutic target, their use is often limited by specific mutation requirements, acquired resistance, or challenging side effects like hyperglycemia.

PIKTOR's potential advantages lie in its design. The new Phase 1b/2 trial, titled "Open-Label Umbrella Study to Evaluate Safety and Efficacy of Sapanisertib and Serabelisib (PIKTOR) in Various Combinations," will enroll HR+/HER2- advanced breast cancer patients regardless of their specific mutational status, broadening its potential applicability. Furthermore, its all-oral formulation offers a significant convenience advantage over intravenous therapies, such as the investigational pan-PI3K/mTOR inhibitor gedatolisib.

The new study, FTH-PIK-101, is designed as a multi-center, dose-escalation trial that will evaluate PIKTOR in combination with fulvestrant and potentially other anticancer agents. This "umbrella" design provides flexibility to explore the most effective combinations for this patient group.

Alongside the new breast cancer trial, Sensei continues to advance PIKTOR in Study FTH-PIK-201, a Phase 2 trial for patients with advanced endometrial cancer. That study is notable for including a substudy investigating whether an insulin-suppressing diet can mitigate metabolic side effects and potentially enhance the drug's efficacy, tackling a known class-wide challenge for PI3K inhibitors head-on. Success across these multiple fronts could establish PIKTOR as a versatile platform therapy for a range of cancers driven by this pervasive growth pathway. For now, all eyes are on the progress of the first patients being treated in this new breast cancer study, which represents a new chapter of hope for those who have run out of options.